PUNE, India, November 26, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Global Repaglinide Industry 2015 Market Research Report" and "Investigation Report on China Repaglinide Market, 2010-2019" reports with 2019 and 2021 forecasts data and information to its online business intelligence library.
Complete report on Repaglinide market spread across 158 pages, profiling 4 companies and supported with 146 tables and figures is now available at http://www.rnrmarketresearch.com/global-repaglinide-industry-2015-market-research-report-market-report.html .
The report provides a basic overview of Repaglinide market including definitions, classifications, applications and industry chain structure. The analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans of Repaglinide market are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand figures, cost price and production value gross margins.
The report focuses on global major Repaglinide market players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Repaglinide market development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.
With 146 tables and figures to support Repaglinide market analysis, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. 4 Companies profiled in this report include Novo Nordisk, Haoson Pharmaceutical, Tianjin Kangrui Pharmaceutical and Beijing Wansheng Pharmaceutical. Order a copy of Global Repaglinide Industry 2015 Market Research Report http://www.rnrmarketresearch.com/contacts/purchase?rname=435178 .
Forecasts provided in this Repaglinide market report include 2016-2021 Repaglinide capacity production overview, production market share, consumption overview, supply consumption and shortage, import export consumption as well as cost price production value gross margin.
Similar research titled "Investigation Report on China Repaglinide Market, 2010-2019" says according to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development. There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million?
In 2000, repaglinide of Novo Nordisk A/S came to be sold in China under the name of Novonorm. According to market survey, it has few rivals and takes up a market share of about 89% for sales value while its main competitor Hanson Pharmaceutical only occupies less than 11% of the market. The sales value of repaglinide in sample hospitals was about CNY 125 million in 2014 and CAGR during the period of 20052014 reached about 22%. Read more at http://www.rnrmarketresearch.com/investigation-report-on-china-repaglinide-market-2010-2019-market-report.html .
The market size of repaglinide is expected to keep growing in the next few years in China.
Readers can get at least the following information through this report: Market size of repaglinide in China, major manufacturers of repaglinide for Chinese market and their market share, retail price of repaglinide in Chinese market and market outlook of repaglinide in China.
The author suggests the following groups of people purchase this report: Manufacturers of antidiabetic drugs, investors/ research institutions interested in Chinese medicine market, any interest in the Chinese medicine market, please contact CRI for customized survey service.
Explore more reports on the Diabetes Drugs market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/diabetes-drugs .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
SOURCE RnR Market Research